Cargando…
Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma
BACKGROUND: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy. Tumor-related glucocorticoid excess is present in ~60% of patients and associated with particularly poor prognosis. Results of first clinical trials using immune checkpoint inhibitors were heterogeneous. Here we characterize...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264832/ https://www.ncbi.nlm.nih.gov/pubmed/32474412 http://dx.doi.org/10.1136/jitc-2019-000469 |
_version_ | 1783541012085342208 |
---|---|
author | Landwehr, Laura-Sophie Altieri, Barbara Schreiner, Jochen Sbiera, Iuliu Weigand, Isabel Kroiss, Matthias Fassnacht, Martin Sbiera, Silviu |
author_facet | Landwehr, Laura-Sophie Altieri, Barbara Schreiner, Jochen Sbiera, Iuliu Weigand, Isabel Kroiss, Matthias Fassnacht, Martin Sbiera, Silviu |
author_sort | Landwehr, Laura-Sophie |
collection | PubMed |
description | BACKGROUND: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy. Tumor-related glucocorticoid excess is present in ~60% of patients and associated with particularly poor prognosis. Results of first clinical trials using immune checkpoint inhibitors were heterogeneous. Here we characterize tumor-infiltrating T lymphocytes (TILs) in ACC in association with glucocorticoids as potential explanation for resistance to immunotherapy. METHODS: We performed immunofluorescence analysis to visualize tumor-infiltrating T cells (CD3(+)), T helper cells (CD3(+)CD4(+)), cytotoxic T cells (CD3(+)CD8(+)) and regulatory T cells (Tregs; CD3(+)CD4(+)FoxP3(+)) in 146 ACC tissue specimens (107 primary tumors, 16 local recurrences, 23 metastases). Quantitative data of immune cell infiltration were correlated with clinical data (including glucocorticoid excess). RESULTS: 86.3% of ACC specimens showed tumor infiltrating T cells (7.7 cells/high power field (HPF)), including T helper (74.0%, 6.7 cells/HPF), cytotoxic T cells (84.3%, 5.7 cells/HPF) and Tregs (49.3%, 0.8 cells/HPF). The number of TILs was associated with better overall survival (HR for death: 0.47, 95% CI 0.25 to 0.87), which was true for CD4(+)− and CD8(+) subpopulations as well. In localized, non-metastatic ACC, the favorable impact of TILs on overall and recurrence-free survival was manifested even independently of ENSAT (European Network for the Study of Adrenal Tumors) stage, resection status and Ki67 index. T helper cells were negatively correlated with glucocorticoid excess (Phi=−0.290, p=0.009). Patients with glucocorticoid excess and low TILs had a particularly poor overall survival (27 vs. 121 months in patients with TILs without glucocorticoid excess). CONCLUSION: Glucocorticoid excess is associated with T cell depletion and unfavorable prognosis. To reactivate the immune system in ACC by checkpoint inhibitors, an inhibition of adrenal steroidogenesis might be pivotal and should be tested in prospective studies. |
format | Online Article Text |
id | pubmed-7264832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-72648322020-06-12 Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma Landwehr, Laura-Sophie Altieri, Barbara Schreiner, Jochen Sbiera, Iuliu Weigand, Isabel Kroiss, Matthias Fassnacht, Martin Sbiera, Silviu J Immunother Cancer Basic Tumor Immunology BACKGROUND: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy. Tumor-related glucocorticoid excess is present in ~60% of patients and associated with particularly poor prognosis. Results of first clinical trials using immune checkpoint inhibitors were heterogeneous. Here we characterize tumor-infiltrating T lymphocytes (TILs) in ACC in association with glucocorticoids as potential explanation for resistance to immunotherapy. METHODS: We performed immunofluorescence analysis to visualize tumor-infiltrating T cells (CD3(+)), T helper cells (CD3(+)CD4(+)), cytotoxic T cells (CD3(+)CD8(+)) and regulatory T cells (Tregs; CD3(+)CD4(+)FoxP3(+)) in 146 ACC tissue specimens (107 primary tumors, 16 local recurrences, 23 metastases). Quantitative data of immune cell infiltration were correlated with clinical data (including glucocorticoid excess). RESULTS: 86.3% of ACC specimens showed tumor infiltrating T cells (7.7 cells/high power field (HPF)), including T helper (74.0%, 6.7 cells/HPF), cytotoxic T cells (84.3%, 5.7 cells/HPF) and Tregs (49.3%, 0.8 cells/HPF). The number of TILs was associated with better overall survival (HR for death: 0.47, 95% CI 0.25 to 0.87), which was true for CD4(+)− and CD8(+) subpopulations as well. In localized, non-metastatic ACC, the favorable impact of TILs on overall and recurrence-free survival was manifested even independently of ENSAT (European Network for the Study of Adrenal Tumors) stage, resection status and Ki67 index. T helper cells were negatively correlated with glucocorticoid excess (Phi=−0.290, p=0.009). Patients with glucocorticoid excess and low TILs had a particularly poor overall survival (27 vs. 121 months in patients with TILs without glucocorticoid excess). CONCLUSION: Glucocorticoid excess is associated with T cell depletion and unfavorable prognosis. To reactivate the immune system in ACC by checkpoint inhibitors, an inhibition of adrenal steroidogenesis might be pivotal and should be tested in prospective studies. BMJ Publishing Group 2020-05-30 /pmc/articles/PMC7264832/ /pubmed/32474412 http://dx.doi.org/10.1136/jitc-2019-000469 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Basic Tumor Immunology Landwehr, Laura-Sophie Altieri, Barbara Schreiner, Jochen Sbiera, Iuliu Weigand, Isabel Kroiss, Matthias Fassnacht, Martin Sbiera, Silviu Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma |
title | Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma |
title_full | Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma |
title_fullStr | Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma |
title_full_unstemmed | Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma |
title_short | Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma |
title_sort | interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma |
topic | Basic Tumor Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264832/ https://www.ncbi.nlm.nih.gov/pubmed/32474412 http://dx.doi.org/10.1136/jitc-2019-000469 |
work_keys_str_mv | AT landwehrlaurasophie interplaybetweenglucocorticoidsandtumorinfiltratinglymphocytesontheprognosisofadrenocorticalcarcinoma AT altieribarbara interplaybetweenglucocorticoidsandtumorinfiltratinglymphocytesontheprognosisofadrenocorticalcarcinoma AT schreinerjochen interplaybetweenglucocorticoidsandtumorinfiltratinglymphocytesontheprognosisofadrenocorticalcarcinoma AT sbieraiuliu interplaybetweenglucocorticoidsandtumorinfiltratinglymphocytesontheprognosisofadrenocorticalcarcinoma AT weigandisabel interplaybetweenglucocorticoidsandtumorinfiltratinglymphocytesontheprognosisofadrenocorticalcarcinoma AT kroissmatthias interplaybetweenglucocorticoidsandtumorinfiltratinglymphocytesontheprognosisofadrenocorticalcarcinoma AT fassnachtmartin interplaybetweenglucocorticoidsandtumorinfiltratinglymphocytesontheprognosisofadrenocorticalcarcinoma AT sbierasilviu interplaybetweenglucocorticoidsandtumorinfiltratinglymphocytesontheprognosisofadrenocorticalcarcinoma |